NASDAQ: PCRXPacira Biosciences Inc Stock
$33.15-0.49 (-1.46%)
Updated Sep 22, 2023
PCRX Price
$33.15
Fair Value Price
$35.31
Market Cap
$1.54B
52 Week Low
$32.67
52 Week High
$58.10
P/E
-301.36x
P/B
1.9x
P/S
2.76x
PEG
N/A
Dividend Yield
N/A
Revenue
$669.23M
Earnings
-$4.57M
Gross Margin
68.6%
Operating Margin
4.44%
Profit Margin
-0.7%
Debt to Equity
0.91
Operating Cash Flow
$147M
Beta
0.87
Next Earnings
Nov 1, 2023
Ex-Dividend
N/A
Next Dividend
N/A
PCRX Overview
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PCRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PCRX ($33.15) is undervalued by 6.11% relative to our estimate of its Fair Value price of $35.31 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
PCRX ($33.15) is not significantly undervalued (6.11%) relative to our estimate of its Fair Value price of $35.31 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PCRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PCRX due diligence checks available for Premium users.
Be the first to know about important PCRX news, forecast changes, insider trades & much more!
PCRX News
Valuation
PCRX fair value
Fair Value of PCRX stock based on Discounted Cash Flow (DCF)
Price
$33.15
Fair Value
$35.31
Undervalued by
6.11%
PCRX ($33.15) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PCRX ($33.15) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PCRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PCRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-301.36x
Industry
26.36x
Market
14.52x
PCRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.9x
Industry
2x
PCRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PCRX's financial health
Profit margin
Revenue
$169.5M
Net Income
$25.8M
Profit Margin
15.2%
PCRX's Earnings (EBIT) of $29.73M... subscribe to Premium to read more.
Interest Coverage Financials
PCRX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.5B
Liabilities
$734.4M
Debt to equity
0.91
PCRX's short-term assets ($429.32M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PCRX's long-term liabilities ($625.49M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PCRX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PCRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$43.5M
Investing
$7.3M
Financing
$440.0k
PCRX's operating cash flow ($147.32M)... subscribe to Premium to read more.
Debt Coverage Financials
PCRX vs Pharmaceutical Stocks
Pacira Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.